Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Regeneron Pharmaceuticals

REGN Healthcare Unknown Updated July 31, 2026
$762.72
52W $541.00 – $821.11
60/100
$78.57B
18.2
0.24
AI Committee Verdict
Buy
Conviction: Contested · 57% agreement · 7 analysts
+6.8%
-4.5%
1.53:1
Contested

Is REGN Bullish or Bearish?

Bullish. Innellis AI committee rates Regeneron Pharmaceuticals (REGN) Buy with a composite score of 60/100 , based on 7 analysts with 57% agreement. Last updated July 31, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +15.24 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -4.76 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.

Bull & Bear Case

Bull Case
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • Low leverage (debt-to-equity 0.09) -- balance sheet can absorb a shock — Risk
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • RSI at 84 is in overbought territory — Technical
  • Price trading above the upper Bollinger Band -- stretched — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of July 31, 2026
Overall Committee Score
60/100
Agreement
57%
Analysts
7
Conviction
Contested
Sector Rank
Top 11%
of 93 Healthcare peers
Value Analyst bullish
62 / 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
Growth Analyst bullish
68 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst neutral
48 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− RSI at 84 is in overbought territory
Risk Analyst bullish
80 / 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.09) -- balance sheet can absorb a shock
Macro Analyst neutral
58 / 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 59.4 to 59.8.

Analyst-level changes:
  • Growth Analyst: stance neutral->bullish; score 52->68 (+17); +2 bullish signal(s).
  • Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
  • News Analyst: stance bullish->neutral; score 64->58 (-6).
  • Portfolio Manager: +2 bearish signal(s).
  • Technical Analyst: +2 bearish signal(s).

Comparing 2026-07-30 to 2026-07-31 (1 day apart).

Technical Analysis

RSI (14)
87.1
Overbought
MACD Histogram
8.865
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Mixed
Support
$728.73
Resistance
$814.64
Bollinger %B
1.25
Above Upper Band
Price vs Moving Averages
EMA 9
$702.26 Above
EMA 21
$678.51 Above
EMA 50
$668.68 Above
EMA 200
$688.47 Above

Fundamental Analysis

Valuation
29
Growth
79
Profitability
1
Financial Health
100
Cash Flow
37
Valuation
P/E Ratio 18.2×
P/B Ratio
PEG Ratio 58.48
Dividend Yield 0.00%
52W High $821.11
52W Low $541.00
Quality & Growth
ROE 14.4%
ROA 11.1%
Gross Margin 83.4%
Operating Margin 24.7%
Revenue Growth YoY
Debt / Equity 0.06
AI Fundamental Assessment
P/E ratio of 18.2 (inexpensive relative to a 15-40x range); Price-to-book of 2486674.9x; PEG ratio of 58.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.1%; Net margin of 0.3%; Gross margin of 0.8%; Current ratio of 3.34 (healthy short-term liquidity); Debt-to-equity of 0.06; Free cash flow margin of 0.8% (thin cash generation); Free cash flow per share is positive (34.06); Most recent quarter beat estimates by 36.5%; 5 consecutive earnings beats; EPS growth accelerating (-17.2% -> +50.9% QoQ); Average YoY EPS growth of 10.9%; Analyst estimates falling over recent quarters
Get the Full REGN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore REGN Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime